Cargando…
Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD
BACKGROUND: Patients with inflammatory bowel disease (IBD) have intestinal inflammation and are treated with immune-modulating medications. In the face of the coronavirus disease-19 pandemic, we do not know whether patients with IBD will be more susceptible to infection or disease. We hypothesized t...
Autores principales: | Burgueño, Juan F, Reich, Adrian, Hazime, Hajar, Quintero, Maria A, Fernandez, Irina, Fritsch, Julia, Santander, Ana M, Brito, Nivis, Damas, Oriana M, Deshpande, Amar, Kerman, David H, Zhang, Lanyu, Gao, Zhen, Ban, Yuguang, Wang, Lily, Pignac-Kobinger, Judith, Abreu, Maria T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188157/ https://www.ncbi.nlm.nih.gov/pubmed/32333601 http://dx.doi.org/10.1093/ibd/izaa085 |
Ejemplares similares
-
Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy
por: Abreu, Maria T, et al.
Publicado: (2022) -
Multidimensional Impact of Mediterranean Diet on IBD Patients
por: Chicco, Fabio, et al.
Publicado: (2020) -
Prediction of Crohn’s Disease Stricturing Phenotype Using a NOD2-derived Genomic Biomarker
por: Ashton, James J, et al.
Publicado: (2022) -
The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s & Colitis Foundation
por: Park, K T, et al.
Publicado: (2020) -
Increased Colonic Epithelial Permeability and Mucosal Eosinophilia in Ulcerative Colitis in Remission Compared With Irritable Bowel Syndrome and Health
por: Katinios, Georgios, et al.
Publicado: (2020)